Studies have shown that CD40 activation can inhibit the survival of many kinds of tumor cells, such as B-cell lymphoma, multiple myeloma, bladder cancer, ovarian cancer, breast cancer, skin cancer and cervical cancer cells, and improve the sensitivity of tumor cells to drugs [4,5], but its effect on cancer radiosensitivity is still unclear. This evidence concerns the gene CD40 and urinary bladder cancer.